Robert Bindert Huizinga is VP at Aurinia Pharmaceuticals Inc. (AUPH). They have made 5 open-market trades across 1 company since 2021, most recently 2022-03-02.
CIK 0001837648
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AUPH | 74,228 | $1.2M |
Shares reported on the most recent Form 4, priced at the 2022-03-04 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AUPH | SELL | 2022-03-02 | 2022-03-04 | $12.01 | $116K | +2.7% | +15.7% | +2.9% |
| AUPH | SELL | 2021-10-25 | 2021-10-26 | $29.75 | $3.9M | +10.0% | -33.5% | -45.9% |
| AUPH | SELL | 2021-09-21 | 2021-09-22 | $23.99 | $1.6M | -10.1% | +19.4% | -3.9% |
| AUPH | SELL | 2021-09-10 | 2021-09-14 | $20.83 | $885K | +9.8% | -0.6% | -6.0% |
| AUPH | SELL | 2021-09-07 | 2021-09-08 | $18.30 | $92K | +10.1% | +1.7% | +6.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.